Novo Nordisk A/S $NVO Shares Sold by Blair William & Co. IL

Key Points

• Blair William & Co. IL reduced its holdings in Novo Nordisk A/S by 11.9%, now owning 43,200 shares valued at approximately $2,982,000.
• Several institutional investors have significantly increased their stakes, with Kingstone Capital Partners boosting holdings by over 301,000% during the same quarter.
• Analysts have mixed views on Novo Nordisk, with price targets varying significantly; TD Cowen lowered its target from $105.00 to $70.00, while Rothschild upgraded it to a "strong-buy" rating.

Blair William & Co. IL cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 11.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 43,200 shares of the company's stock after selling 5,819 shares during the period. Blair William & Co. IL's holdings in Novo Nordisk A/S were worth $2,982,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of NVO. Kingstone Capital Partners Texas LLC boosted its holdings in Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company's stock worth $690,560,000 after buying an additional 10,001,898 shares during the last quarter. Nuveen LLC acquired a new stake in Novo Nordisk A/S in the 1st quarter worth about $370,272,000. Amundi boosted its holdings in Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company's stock worth $331,576,000 after buying an additional 1,627,051 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Novo Nordisk A/S by 15,919.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock worth $72,523,000 after buying an additional 1,038,137 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Novo Nordisk A/S by 118.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,594,544 shares of the company's stock worth $110,725,000 after buying an additional 864,579 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the topic of several research analyst reports. TD Cowen lowered their price objective on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, August 19th. Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a report on Tuesday, September 16th. Morgan Stanley cut Novo Nordisk A/S from an "overweight" rating to an "underweight" rating and lowered their target price for the stock from $59.00 to $47.00 in a report on Monday, September 29th. Finally, Rothschild Redb upgraded Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Moderate Buy" and a consensus target price of $77.50.

Novo Nordisk A/S Trading Up 1.0%

NVO opened at $57.51 on Tuesday. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $120.47. The stock has a market capitalization of $256.76 billion, a PE ratio of 15.80, a P/E/G ratio of 2.58 and a beta of 0.68. The business's 50 day moving average price is $55.61 and its 200 day moving average price is $63.03. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is currently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.